Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > November 8, 2024
Daily News
November 8, 2024
- Self-Medication and Proper Drug Pricing 2 Sides of the Same Coin: Professor
November 8, 2024
- Lilly’s Pediatric Development Efforts Bore Fruit This Year: Japan CMO
November 8, 2024
- MHLW Issues Guidance on Early Approval Scheme for MCMs
November 8, 2024
- Santen Bags Commercial Rights to Uveitic Macular Edema Drug in China
November 8, 2024
- Keytruda Grabs Top-Selling Crown for 13th Month in October: Encise
November 8, 2024
- Private-Academia Collab Yields 8 Pediatric Drug Approvals in Japan
November 8, 2024
Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…